AIOS pivot to UK branded supply
$400M/year GLP-1 wrapper
The revenue drop showed that AIOS was never just selling weight loss prescriptions, it was selling access to whichever GLP-1 supply lane was legally open. In the US, that lane slammed shut when compounding ended, so the ad driven machine suddenly had less product to push. Buying Bolt gave AIOS a new lane in the UK, where branded drug supply was legal, prices were nationally anchored, and private demand was large because NHS access stayed tight.
-
The mechanics changed from high margin compounded medicine in the US to pharmacy passthrough in the UK. Patients still filled out a short intake, got reviewed by a prescriber, and received monthly shipments, but in Britain AIOS won by listing branded Wegovy and Mounjaro at the lowest cash pay price, not by compounding its own supply.
-
Bolt mattered because it bundled licensing with a ready made storefront. AIOS did not have to slowly build a UK clinic, pharmacy operation, and brand from scratch. It could plug its paid acquisition system into an existing regulated pharmacy and scale volume fast, helping active patients grow from roughly 3,000 to 150,000 in 12 months.
-
This rebound came with a tradeoff. Revenue recovered faster than gross profit, because most UK sales dollars pass straight through to Eli Lilly and Novo Nordisk. That makes AIOS look more like a high volume pharmacy at roughly 20% gross margins, versus Ro and Hims & Hers at 65% to 80% when they keep more of the fulfillment economics.
The next phase is a race to own regulated distribution before drug makers and larger telehealth platforms do. AIOS is pushing the Bolt playbook across Europe, while Hims entered the UK through ZAVA and Ro locked in branded supply through NovoCare. The companies that secure pharmacy rails now will control demand when GLP-1 use keeps spreading.